| (19) |
 |
|
(11) |
EP 2 574 341 A8 |
| (12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
Note: Bibliography reflects the latest situation |
| (15) |
Correction information: |
|
Corrected version no 1 (W1 A1) |
| (48) |
Corrigendum issued on: |
|
22.05.2013 Bulletin 2013/21 |
| (88) |
Date of publication A3: |
|
03.04.2013 Bulletin 2013/14 |
| (43) |
Date of publication: |
|
03.04.2013 Bulletin 2013/14 |
| (22) |
Date of filing: 29.03.2005 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI
SK TR |
| (30) |
Priority: |
29.03.2004 US 557599 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
05746910.8 / 1737472 |
| (71) |
Applicant: UNIVERSITY OF SOUTH FLORIDA |
|
Tampa, FL 33612 (US) |
|
| (72) |
Inventors: |
|
- Cheng, Jin Q.
Tampa, FL Florida 33647 (US)
- Sebti, Said M.
Tampa, FL Florida 33647 (US)
|
| (74) |
Representative: Fanelli Haag Kilger PLLC |
|
Fasanenstrasse 29
10719 Berlin
10719 Berlin (DE) |
|
| |
|
|
|
Remarks: |
|
This application was filed on 17-12-2012 as a divisional application to the application
mentioned under INID code 62. |
|
| (54) |
Effective treatment of tumors and cancer with triciribine and related compounds |
(57) The inventors have determined, contrary to the prior art and experience, how to successfully
use triciribine to treat tumors and cancer by one or a combination of (i) administering
triciribine only to patients which according to a diagnostic test described below,
exhibit enhanced sensitivity to the drug, (ii) use of a described dosage level that
minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of
a described dosage regiment that minimizes the toxicity of the drug.